Summary
Professor Morice is Head of Respiratory Medicine at HYMS, based at the University of Hull. He is also an Honorary Consultant Physician at Hull & East Yorkshire Hospitals NHS Trust. Professor Morice specialises in the diagnosis and treatment of cough, and runs the Hull Cough Clinic. He also runs the Hull Respiratory Clinical Trials Unit, specialising in the treatment of asthma and COPD.
The Hull Cough Clinic is one of the largest centres within Europe, with an international pattern of referral. Unique investigational strategies provide diagnosis and treatment advances, which are incorporated into national and international guideline documents.
Professor Morice has led the European Respiratory Society and British Thoracic Society Taskforces on Cough.
HYMS plenary lectures
The pharmacology of the autonomic nervous system
Regulation of breathing and cough
Pharmacology of airways obstruction
HYMS Year 3 Cardiovascular Respiratory & Dermatology (CVRSD) group, teaching on Cough (3x per semester)
Journal Article
Efficacy and safety of pharmacotherapy for refractory or unexplained chronic cough: a systematic review and network meta-analysis
Zheng, Z., Huang, J., Xiang, Z., Wu, T., Lan, X., Xie, S., …Chen, R. (2023). Efficacy and safety of pharmacotherapy for refractory or unexplained chronic cough: a systematic review and network meta-analysis. EClinicalMedicine, 62, Article 102100. https://doi.org/10.1016/j.eclinm.2023.102100
Burden of chronic cough in the UK: results from the 2018 National Health and Wellness Survey
McGarvey, L., Morice, A. H., Martin, A., Li, V. W., Doane, M. J., Urdaneta, E., …Fonseca, E. (2023). Burden of chronic cough in the UK: results from the 2018 National Health and Wellness Survey. ERJ Open Research, 9(4), Article 00157-2023. https://doi.org/10.1183/23120541.00157-2023
Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study
Dicpinigaitis, P. V., Morice, A. H., Smith, J. A., Sher, M. R., Vaezi, M., Guilleminault, L., …McGarvey, L. (2023). Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study. Lung, 201, Article 255-266. https://doi.org/10.1007/s00408-023-00621-x
The "vicious circle" of chronic cough: The patient experience – qualitative synthesis
Brindle, K., Morice, A., Carter, N., Sykes, D., Zhang, M., & Hilton, A. (2023). The “vicious circle” of chronic cough: The patient experience – qualitative synthesis. ERJ Open Research, 9(3), Article 00094-2023. https://doi.org/10.1183/23120541.00094-2023
Research interests
Professor Morice specialises in the diagnosis and treatment of cough, and runs the Hull Cough Clinic. He also runs the Hull Respiratory Clinical Trials Unit, specialising in the treatment of asthma and COPD.
The Hull Cough Clinic is one of the largest centres within Europe, with an international pattern of referral. Unique investigational strategies provide diagnosis and treatment advances, which are incorporated into national and international guideline documents.
Professor Morice has led the European Respiratory Society and British Thoracic Society Taskforces on Cough.
Lead investigator
Project
Funder
Grant
Started
Status
Project
Phase 2a, Randomised, Double-Blind, Placebo-Controlled, Two-Part Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetic Profiles of Inhaled Doses of NOC-100 in Adult Participants with Chronic or Acute Cough
Funder
Hull University Teaching Hospitals NHS Trust
Grant
£123,936.00
Started
1 November 2021
Status
Ongoing
Project
Two-part, double-blind, placebo-controlled, randomized, parallel-group study - (Part 1) in healthy male volunteers to assess safety and tolerability of ascending repeated oral doses of BAY 1817080 followed (Part 2), two-way crossover administration with four-step dose titration in patients with refractory chronic cough to assess safety, tolerability and efficacy for proof of concept and dose-finding
Funder
Bayer Pharma AG
Grant
£61,101.00
Started
18 July 2018
Status
Complete
Project
AX-8 Clinical Research Collaboration
Funder
Hull University Teaching Hospitals NHS Trust
Grant
£21,285.00
Started
1 June 2016
Status
Complete
Project
BICS: A randomised, double-blind placebo controlled trial of the effectiveness of the beta-blocker bisoprolol in preventing exacerbations of chronic obstructive pulmonary disease
Funder
NIHR National Institute for Health Research
Grant
£27,108.00
Started
1 June 2017
Status
Complete
Project
VOLCANO-2: A double-blind, placebo controlled study of the efficacy and safety of three doses of Orvepitant in subjects with chronic refractory cough
Funder
Hull University Teaching Hospitals NHS Trust
Grant
£42,493.00
Started
1 August 2017
Status
Complete
Project
Lavolta - A phase III, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of
Funder
Hull University Teaching Hospitals NHS Trust
Grant
£19,047.00
Started
18 May 2014
Status
Complete
Project
OSPREY: An Observational Study of the Phenotype and pRescribing in East Yorkshire and its relevance to the introduction of new prescribing guidelines for airways disease.
Funder
AstraZeneca UK Limited
Grant
£163,413.00
Started
1 October 2016
Status
Complete
Project
Orbit-4: A multi-centre, randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of Pulmaquin in the management of chronic lung infections with pseudomonas aeruginosa in subjects with non-cystic fibrosis bronchiectasis, including 28
Funder
Aradigm Corporation
Grant
£30,144.00
Started
31 October 2014
Status
Complete
Project
TUF: The Utility of FeNo in the differential diagnosis of chronic cough
Funder
Aerocrine AB
Grant
£30,000.00
Started
2 November 2015
Status
Complete
Project
Development Costs: A Study to Assess the Effect of AF-219 on Cough Reflex Sensitivity in Both Healthy and Chronic Cough Subjects
Funder
Afferent Pharmaceuticals Inc
Grant
£62,207.00
Started
5 October 2015
Status
Complete
Project
AFFERENT14: A Study to Assess the Effect of AF-219 on Cough Reflex Sensitivity in Both Healthy and Chronic Cough Subjects
Funder
Afferent Pharmaceuticals Inc
Grant
£140,667.00
Started
5 October 2015
Status
Complete
Project
AFFERENT12: AF219-012: A 12 week Study to assess the Efficacy and tolerability of AF 219 in subjects with treatm
Funder
Afferent Pharmaceuticals Inc
Grant
£22,020.00
Started
1 March 2016
Status
Complete
Project
Proof of Concept study (POC) to investigate the effect of ambroxol hydrochloride (20mg lozenges) on the cough reflex in patients with acute upper respiratory tract infection
Funder
Sanofi Aventis
Grant
£27,342.00
Started
1 October 2017
Status
Complete
Project
RELIEF: A Randomised, Double-blind, Placebo-Controlled, Crossover, Dose Escalation Study of BLU-5937 in subjects with Unexplained or Refractory Chronic Cough
Funder
Hull University Teaching Hospitals NHS Trust
Grant
£22,286.00
Started
1 June 2020
Status
Complete
Project
TUSSIX: MTI-110 - A randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of Serlopitant for the treatment of refractory chronic cough
Funder
Hull University Teaching Hospitals NHS Trust
Grant
£16,546.00
Started
1 December 2017
Status
Complete
Project
Randomised, double-blind, parallel group. Phase 2b dose-finding, efficacy and safety study of 12-week twice daily oral administration of BAY 1817080 compared to placebo in the treatment of refractory and/or unexplained chronic cough (RUCC)
Funder
Hull University Teaching Hospitals NHS Trust
Grant
£26,613.00
Started
1 January 2021
Status
Complete